ArticleBMC medicine2026

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study.

Xiaoyu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.